Trial Profile
A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 06 Jan 2021 This trial is completed in Belgium, according to European Clinical Trials Database record.
- 30 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Aug 2020 Planned End Date changed from 15 Dec 2020 to 18 Dec 2020.